Výsledky vyhledávání - Robert A. Burger

Upřesnit hledání
  1. 1
    HIF Inactivation of p53 in Ovarian Cancer Can Be Reversed by Topotecan, Restoring Cisplatin and Paclitaxel Sensitivity

    HIF Inactivation of p53 in Ovarian Cancer Can Be Reversed by Topotecan, Restoring Cisplatin and Paclitaxel Sensitivity Autor Basmina Parmakhtiar, Robert A. Burger, Jai-Hyun Kim, John P. Fruehauf

    Vydáno 2019
    Získat plný text
    Artigo
    Přidat do oblíbených
    Uloženo v:
  2. 2
    Prognostic factors in neuroendocrine small cell cervical carcinoma

    Prognostic factors in neuroendocrine small cell cervical carcinoma Autor John K. Chan, Vera Loizzi, Robert A. Burger, Joanne Rutgers, Bradley J. Monk

    Vydáno 2003
    Získat plný text Získat plný text
    Artigo
    Přidat do oblíbených
    Uloženo v:
  3. 3
    Early initiation of chemotherapy following complete resection of advanced ovarian cancer associated with improved survival: NRG Oncology/Gynecologic Oncology Group study

    Early initiation of chemotherapy following complete resection of advanced ovarian cancer associated with improved survival: NRG Oncology/Gynecologic Oncology Group study Autor Krishnansu S. Tewari, James Java, Ramez N. Eskander, Bradley J. Monk, Robert A. Burger

    Vydáno 2015
    Získat plný text
    Artigo
    Přidat do oblíbených
    Uloženo v:
  4. 4
    Phase II Trial of Bevacizumab in Persistent or Recurrent Epithelial Ovarian Cancer or Primary Peritoneal Cancer: A Gynecologic Oncology Group Study

    Phase II Trial of Bevacizumab in Persistent or Recurrent Epithelial Ovarian Cancer or Primary Peritoneal Cancer: A Gynecologic Oncology Group Study Autor Robert A. Burger, Michael W. Sill, Bradley J. Monk, Benjamin E. Greer, Joel I. Sorosky

    Vydáno 2007
    Získat plný text Získat plný text
    Artigo
    Přidat do oblíbených
    Uloženo v:
  5. 5
    Phase II Trial of Bevacizumab in the Treatment of Persistent or Recurrent Squamous Cell Carcinoma of the Cervix: A Gynecologic Oncology Group Study

    Phase II Trial of Bevacizumab in the Treatment of Persistent or Recurrent Squamous Cell Carcinoma of the Cervix: A Gynecologic Oncology Group Study Autor Bradley J. Monk, Michael W. Sill, Robert A. Burger, Heidi J. Gray, Thomas Buekers, Lynda D. Roman

    Vydáno 2009
    Získat plný text Získat plný text
    Artigo
    Přidat do oblíbených
    Uloženo v:
  6. 6
    Independent radiologic review of the Gynecologic Oncology Group Study 0218, a phase III trial of bevacizumab in the primary treatment of advanced epithelial ovarian, primary peritoneal, or fallopian tube cancer

    Independent radiologic review of the Gynecologic Oncology Group Study 0218, a phase III trial of bevacizumab in the primary treatment of advanced epithelial ovarian, primary perito... Autor Robert A. Burger, Mark F. Brady, Joon Haeng Rhee, Mika A. Sovak, George Kong, Hoa Nguyen, Michael A. Bookman

    Vydáno 2013
    Získat plný text
    Artigo
    Přidat do oblíbených
    Uloženo v:
  7. 7
    Human Papillomavirus Type 18: Association With Poor Prognosis in Early Stage Cervical Cancer

    Human Papillomavirus Type 18: Association With Poor Prognosis in Early Stage Cervical Cancer Autor Robert A. Burger, Bradley J. Monk, Tom Kurosaki, Hoda Anton‐Culver, Steven A. Vasilev, Michael L. Berman, Sharon P. Wilczynski

    Vydáno 1996
    Získat plný text Získat plný text
    Revisão
    Přidat do oblíbených
    Uloženo v:
  8. 8
    Incidence of Venous Thromboembolism by Type of Gynecologic Malignancy and Surgical Modality in the National Surgical Quality Improvement Program

    Incidence of Venous Thromboembolism by Type of Gynecologic Malignancy and Surgical Modality in the National Surgical Quality Improvement Program Autor Ashley Graul, Nawar Latif, Xiaochen Zhang, Lorraine T. Dean, Mark A. Morgan, Robert Giuntoli, Robert A. Burger, Sarah Kim, Emily Ko

    Vydáno 2017
    Získat plný text
    Artigo
    Přidat do oblíbených
    Uloženo v:
  9. 9
    Analysis of gene expression profiles in normal and neoplastic ovarian tissue samples identifies candidate molecular markers of epithelial ovarian cancer

    Analysis of gene expression profiles in normal and neoplastic ovarian tissue samples identifies candidate molecular markers of epithelial ovarian cancer Autor John Welsh, Patrick P. Zarrinkar, Lisa M. Sapinoso, S Kern, Cynthia Behling, Bradley J. Monk, David J. Lockhart, Robert A. Burger, Garret M. Hampton

    Vydáno 2001
    Získat plný text
    Artigo
    Přidat do oblíbených
    Uloženo v:
  10. 10
    Intraperitoneal Cisplatin and Paclitaxel in Ovarian Cancer

    Intraperitoneal Cisplatin and Paclitaxel in Ovarian Cancer Autor Deborah K. Armstrong, Brian N. Bundy, Lari Wenzel, Helen Q. Huang, Rebecca N. Baergen, Shashikant Lele, Larry J. Copeland, Joan L. Walker, Robert A. Burger

    Vydáno 2006
    Získat plný text Získat plný text
    Artigo
    Přidat do oblíbených
    Uloženo v:
  11. 11
    Tumor Microvessel Density as a Potential Predictive Marker for Bevacizumab Benefit: GOG-0218 Biomarker Analyses

    Tumor Microvessel Density as a Potential Predictive Marker for Bevacizumab Benefit: GOG-0218 Biomarker Analyses Autor Carlos Bais, Barbara M. Mueller, Mark F. Brady, Robert S. Mannel, Robert A. Burger, Wei Wei, Koen M. Marien, Mark Kockx, Amreen Husain, Michael J. Birrer

    Vydáno 2017
    Získat plný text Získat plný text
    Artigo
    Přidat do oblíbených
    Uloženo v:
  12. 12
    Markers of angiogenesis in high-risk, early-stage cervical cancer: A Gynecologic Oncology Group study

    Markers of angiogenesis in high-risk, early-stage cervical cancer: A Gynecologic Oncology Group study Autor Leslie M. Randall, Bradley J. Monk, Kathleen M. Darcy, Chunqiao Tian, Robert A. Burger, Shu‐Yuan Liao, William A. Peters, Richard J. Stock, John P. Fruehauf

    Vydáno 2008
    Získat plný text
    Artigo
    Přidat do oblíbených
    Uloženo v:
  13. 13
    Maintenance Treatment with Bevacizumab Prolongs Survival in an<i>In vivo</i>Ovarian Cancer Model

    Maintenance Treatment with Bevacizumab Prolongs Survival in an<i>In vivo</i>Ovarian Cancer Model Autor Seiji Mabuchi, Yoshito Terai, Kenichiro Morishige, Akiko Tanabe-Kimura, Hiroshi Sasaki, Masanori Kanemura, Satoshi Tsunetoh, Yoshimichi Tanaka, Masahiro Sakata, Robert A. Burger, Tadashi Kimura, Masahide Ohmichi

    Vydáno 2008
    Získat plný text Získat plný text
    Artigo
    Přidat do oblíbených
    Uloženo v:
  14. 14
    Phase III Trial of Doxorubicin Plus Cisplatin With or Without Paclitaxel Plus Filgrastim in Advanced Endometrial Carcinoma: A Gynecologic Oncology Group Study

    Phase III Trial of Doxorubicin Plus Cisplatin With or Without Paclitaxel Plus Filgrastim in Advanced Endometrial Carcinoma: A Gynecologic Oncology Group Study Autor Gini F. Fleming, Virginia L. Brunetto, David Cella, Katherine Y. Look, Gary C. Reid, Adnan Munkarah, Richard Kline, Robert A. Burger, Annekathryn Goodman, R. Tucker Burks

    Vydáno 2004
    Získat plný text Získat plný text
    Artigo
    Přidat do oblíbených
    Uloženo v:
  15. 15
    Patient reported outcomes of a randomized, placebo-controlled trial of bevacizumab in the front-line treatment of ovarian cancer: A Gynecologic Oncology Group Study

    Patient reported outcomes of a randomized, placebo-controlled trial of bevacizumab in the front-line treatment of ovarian cancer: A Gynecologic Oncology Group Study Autor Bradley J. Monk, Helen Q. Huang, Robert A. Burger, Robert S. Mannel, Howard D. Homesley, Jeffrey M. Fowler, Benjamin E. Greer, Matthew Boente, Sharon X. Liang, Lari Wenzel

    Vydáno 2012
    Získat plný text
    Artigo
    Přidat do oblíbených
    Uloženo v:
  16. 16
    Prognostic relevance of carbonic anhydrase-IX in high-risk, early-stage cervical cancer: A Gynecologic Oncology Group study

    Prognostic relevance of carbonic anhydrase-IX in high-risk, early-stage cervical cancer: A Gynecologic Oncology Group study Autor Shu‐Yuan Liao, Kathleen M. Darcy, Leslie M. Randall, Chunqiao Tian, Bradley J. Monk, Robert A. Burger, John P. Fruehauf, William A. Peters, Richard J. Stock, Eric J. Stanbridge

    Vydáno 2009
    Získat plný text
    Artigo
    Přidat do oblíbených
    Uloženo v:
  17. 17
    Phase II Study of Bevacizumab in Patients With Platinum-Resistant Ovarian Cancer or Peritoneal Serous Cancer

    Phase II Study of Bevacizumab in Patients With Platinum-Resistant Ovarian Cancer or Peritoneal Serous Cancer Autor Stephen A. Cannistra, Ursula A. Matulonis, Richard T. Penson, Julie Hambleton, Jakob Dupont, Howard Mackey, Jeffrey A. Douglas, Robert A. Burger, Deborah K. Armstrong, Robert M. Wenham, William P. McGuire

    Vydáno 2007
    Získat plný text Získat plný text
    Artigo
    Přidat do oblíbených
    Uloženo v:
  18. 18
    Ascites predicts treatment benefit of bevacizumab in front-line therapy of advanced epithelial ovarian, fallopian tube and peritoneal cancers: An NRG Oncology/GOG study

    Ascites predicts treatment benefit of bevacizumab in front-line therapy of advanced epithelial ovarian, fallopian tube and peritoneal cancers: An NRG Oncology/GOG study Autor J. Stuart Ferriss, James Java, Michael A. Bookman, Gini F. Fleming, Bradley J. Monk, Joan L. Walker, Howard D. Homesley, Jeffrey M. Fowler, Benjamin E. Greer, Matthew Boente, Robert A. Burger

    Vydáno 2015
    Získat plný text
    Artigo
    Přidat do oblíbených
    Uloženo v:
  19. 19
    Predictive and prognostic angiogenic markers in a gynecologic oncology group phase II trial of bevacizumab in recurrent and persistent ovarian or peritoneal cancer

    Predictive and prognostic angiogenic markers in a gynecologic oncology group phase II trial of bevacizumab in recurrent and persistent ovarian or peritoneal cancer Autor Ernest Han, Robert A. Burger, Kathleen M. Darcy, Michael W. Sill, Leslie M. Randall, Dana M. Chase, Basmina Parmakhtiar, Bradley J. Monk, Benjamin E. Greer, Patrick J. Connelly, Koen DeGeest, John P. Fruehauf

    Vydáno 2010
    Získat plný text
    Artigo
    Přidat do oblíbených
    Uloženo v:
  20. 20
    Vascular Endothelial Growth Factor Is a Promising Therapeutic Target for the Treatment of Clear Cell Carcinoma of the Ovary

    Vascular Endothelial Growth Factor Is a Promising Therapeutic Target for the Treatment of Clear Cell Carcinoma of the Ovary Autor Seiji Mabuchi, Chiaki Kawase, Deborah A. Altomare, Ken‐ichirou Morishige, Masami Hayashi, Kenjiro Sawada, Kimihiko Ito, Yoshito Terai, Yukihiro Nishio, Andres J. Klein–Szanto, Robert A. Burger, Masahide Ohmichi, Joseph R. Testa, Tadashi Kimura

    Vydáno 2010
    Získat plný text
    Artigo
    Přidat do oblíbených
    Uloženo v:

Vyhledávací nástroje: